SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001144204-18-005239
Filing Date
2018-02-01
Accepted
2018-02-01 18:41:14
Documents
1
Period of Report
2018-01-30

Document Format Files

Seq Description Document Type Size
1 FORM 4 tv484690_form4.html 4  
1 FORM 4 tv484690_form4.xml 4 4188
  Complete submission text file 0001144204-18-005239.txt   5593
Mailing Address C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK NY 10022
Business Address
Oliviero James F III (Reporting) CIK: 0001434718 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38128 | Film No.: 18568144

Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Issuer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences